MAR 29, 2017 02:13 PM PDT

Immune Stem Cells Treat the Most Common Type of Liver Cancer

WRITTEN BY: Kara Marker

There are more multiple causes of hepatocellular carcinoma (HCC) and more than five approaches to treating it. Well, add one more to the list. Combining stem cell science and immunotherapy techniques, Kumamoto University scientists might be on the brink of the most effective treatment yet, for a condition that is the most common form of liver cancer and which has an unfortunately high mortality rate.

An illustration of immune stem cells. Credit: SEPCELL

Several conditions increase a person’s risk of developing HCC: hepatitis B, hepatitis C, cirrhosis, obesity, diabetes, iron buildup in the liver, exposure to aflatoxins produced by fungi on some types of food. Radiation, chemotherapy, cryo- or radiofrequency ablation, resection, and liver transplants are all options doctors might consider to treat a person with HCC, but the five-year survival rate is still less than 50 percent, and that’s just for localized cases of cancer, where the liver tumors have not yet metastasized.

A new study, published in the Journal of Hepato-Biliary-Pancreatic Sciences, might be the beginning of a completely new option to improve the five-year survival rate for HCC.

Induced pluripotent stem cells (iPSCs) are cells that are useful in experimental medicine because of their innate ability to become multiple cell types. In the present study, researchers designed immune cells derived from iPSCs, specifically immune cells that produce a protein called interferon-beta (INF-B).

INF-B is recruited by the immune system for two reasons: antiviral abilities and two different types of antitumor activity. Despite their antitumor activity, INF-B proteins cause several problems when implemented into anti-cancer therapies, including accelerated inactivation, poor tissue penetrations, and toxicity.

Kumamoto researchers saw a way around these roadblocks, developing a method to design cells that provide all of the benefits of a INF-B anti-cancer approach without all of the problems and negative side effects: iPSC-derived proliferating myelomonocytic cells (iPS-ML cells).

iPS-ML cell activity resembles the activity of another type of immune cell, tumor-associated macrophages (TAMs). Along with regulatory T cells, TAMs are the primary tumor-promoting immune cells in the tumor microenvironment. With iPS-ML cells appearing to be also capable of promoting tumors, Kumomoto researchers quickly realized them to be the perfect vessel for “sneaking” INF-B into the the tumor microenvironment.

The image above is adapted from the Kumamoto University study results: (A) Bio-imaging analysis to evaluate the therapeutic effect of iPS-ML producing IFN-β on metastatic liver cancer. (B) Quantification of the image data shown in A. (C) Histological data indicating migration of iPS-ML (PKH26, red) into intrahepatic tumor tissues (GFP, green). Credit: Associate Professor Satoru Senju

 

A mouse study quickly confirmed the potential of iPS-ML/INF-B cells. They found that mice livers with tumors had higher levels of IFN-B than livers without tumors. This is because iPS-ML/IFN-B cells did not penetrate not-tumorous livers, instead they remained on the surface of the healthy organs.

Additionally, they found that IFN-B levels in liver tumors one to three days after the initial injection of iPS-ML/INF-B were high enough to inhibit proliferation or even cause death of tumor cells.

“iPS-cell derived, IFN-β expressing myeloid cells should be beneficial for many cancer patients," said research leader Dr. Satoru Senju. "If it is determined to be safe for human use, this technology has the potential to slow cancer progression and increase survival rates.”

Sources: American Cancer Society, Cellular and Molecular Immunology, Kumamoto University

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 02, 2018
Immunology
AUG 02, 2018
Chronic Infections Outsmart the Immune System
Chronic parasitic infection shown to take advantage of a mechanism to sustain infection and induce death of white blood cells essential to immune response....
AUG 22, 2018
Immunology
AUG 22, 2018
Immune Response Runs on the Body Clock
Immune cell functions such as inflammation are dictated by your bodies circadian rhythm, responding daily to external stimuli on a 24 hour schedule....
AUG 24, 2018
Cell & Molecular Biology
AUG 24, 2018
Chronic Allergies can Change Cells
Chronic rhinosinusitis is different from allergies; it leads to serious inflammation and swelling in the sinuses that can last for years....
SEP 04, 2018
Immunology
SEP 04, 2018
Development of Damaging Immune Cells in Tuberculosis Infection
Development of damaging white blood cells occurs during Tuberculosis infection leading to a maladaptive immune response....
SEP 10, 2018
Immunology
SEP 10, 2018
The Immune System: A New Hope for Opioid Addiction?
Addiction, Immunology, Opioid...
NOV 07, 2018
Drug Discovery
NOV 07, 2018
Modifying Antibiotics For Drug Resistant Infections
In a study published in Nature Chemistry, researches at MIT were able to create a new chemical reaction that has the ability to modify antibiotics to make ...
Loading Comments...